Scailyte closes Series A funding with a CHF 6 million investment to develop strategic partnerships in immuno-oncology

Scailyte’s priorities will be focused on advancing the endometriosis biomarker into the prototype validation stage in the United States as the primary target market. In addition, the company is building strategic partnerships in single-cell omics, cell & gene therapy, and translational oncology to increase the success rate of novel cancer therapies in the clinic. Scailyte is also expanding the discovery capabilities of ScaiVision, our best-in-class single-cell analytics platform.

“The continuously increasing failure rate of highly anticipated new cancer immuno-therapies in combination with recent FDA’s considerations to step away from animal models is leading to both: unprecedented challenges for translational oncology, and exciting opportunities for clinically relevant alternative models. We are proud to be working with Nilogen Oncosystems in developing a joint platform using fresh patient tumor tissues, a cutting-edge omics engine, and computational tools for evaluating the mechanism of action and efficacy of immuno-oncology therapies. We aim at supporting faster and data-driven decision-making in drug development, increasing the success rate in clinical trials, and advancing personalized cancer treatment”, said Juana Lucia Flores-Candia, Ph.D., MBA, VP of Strategy & Business Development at Scailyte.

Scailyte won Venture Kick in 2017, participated in Venture Leaders Life Sciences in 2019, and was selected for the TOP 100 Swiss Startups Awards from 2019 to 2021. "Venture Leaders Life Sciences brings together a group of 10 promising Swiss Medtech/Biotech startups, which offers valuable exchange between peers, as well as makes it attractive for investors to meet with the group and open doors for the startups. You can think of the program as a premium Swiss chocolate box: there is something sweet for everyone in it," said Peter Nestorov, CEO of Scailyte.

Source: Scailyte Press Release